LinkedIn Logo

February 20-22, 2018

Boston, USA

Day One
Wednesday, February 21, 2018

Day Two
Thursday, February 22nd, 2018

08.25
Chairs Welcoming & Opening Remarks

Novel Therapeutic Approaches for Targeting Neuroinflammation & Neurodegeneration

08.30
(Re) Introduction to Microglia as Intrinsic Brain Cells

  • Richard Ransohoff Previously VP & Senior Research Fellow Neuroimmunology (Biogen), Harvard Medical School

Synopsis

  • Demonstrating the role of microglia enter the developing CNS in early embryogenesis and carry out crucial developmental tasks
  • Highlighting how basal and reactive microglial transcriptomes point towards mechanisms underlying functions
  • Showcasing how our microglial research tool kit continues to grow but still lacks some desirable utensils

08.50
Targeting Innate and Adaptive Immune Mechanisms to Modulate Neurodegeneration

Synopsis

  • Reviewing accumulating evidence suggesting that proliferation of microglia has an important role in neurodegeneration
  • Demonstrating data showing innate and adaptive immune mechanisms as important factors in controlling proliferation and function of microglia in AD

09.10
Shedding Light on the Role of TREM2 in Alzheimer’s Disease

  • Damian Crowther Director, R&D Neuroscience IMED Biotech Unit, AstraZeneca

Synopsis

  • Demonstrating how TREM2 shedding from the microglia leaves them “blind” to debris in the brain
  • Exploring how shed TREM2 is increased in neurological diseases and accelerated shedding is linked to Alzheimer’s disease
  • Proteolysis occurs at a single position in the protein, providing a target for therapy

09.30
The Importance of Microtubular Proteins & Cytokines in Neuroplasticity & Neuroinflammation

Synopsis

  • Exploring the interplay between alterations in microtubular proteins and cytokines in neuroinflammation and neuroplasticity
  • Demonstrating CSF data highlighting the relationship between a-syn, Tau and microtubules and their effects on plasticity
  • Evaluating the interaction between microtubular proteins and cytokines and possible pharmacological interventions

09.50
Session Q&A Panel

Synopsis

  • What is the pathological role of neuroinflammation and the immune system in the development of neurodegenerative diseases?
  • How should we be targeting and/or developing dynamic therapeutic strategies for tackling neuroinflammation?
  • How can genetics drive the identification of novel targets for immune-based therapy towards microglial and neuroinflammation in neurodegenerative disorders?

10.30
Speed Networking & Morning Refreshments

11.30 Systems Biology Approaches to Accelerating Neurodegenerative Drug Discovery

  • Demonstrating how large-scale genomic datasets can be used to tackle three core challenges in CNS drug discovery and development:
  • Identifying next-generation therapeutic targets; Selection of appropriate preclinical disease models; Patient enrichment strategies and biomarker
    discovery
  • Exploring how can patient derived iPSc’s can be combined with patient genetic and gene expression data to create an “all-in-human” approach to drug discovery

Alice Zhang, CEO, Verge Genomics

11.50 Transcriptomic Profiling & Experimental Validation to Explore Drug Repurposing in Parkinson’s Disease

  • Exploring the value of using iPSC-derived dopamine neurons generated from Parkinson’s patients in research
  • Highlighting the importance of experimental validation of an in silico prediction in robust models of Parkinson’s
  • The central role of lysosomal biology in Parkinson’s
  • Does transcriptomic analysis of disease models provide a short-cut to drug repurposing?

Richard Wade-Martins, Professor Molecular Neuroscience, University of Oxford

12.10 Modulation of Histone Modifying Enzymes for Treatment of Neurodegenerative Disease

  • Demonstrating the modulation of the histone lysine demethylase, LSD1, has positive effects on cognition and neuroinflammation in different animal models of neurodegenerative disease
  • ORY-2001 has finalized Phase I studies and is ready for the trials in patients with neurodegenerative disease

Tamara Maes, CSO and VP, Oryzon Genomics S.A.

12.30 Session Q&A Panel

  • Where can genetics and big data be best utilized to drive the identification of novel pathway and target selections?
  • Can genetic profiles be utilized to identify higher risk patient populations in earlier phases of disease initiation?
  • How should we factor in the dynamic relationships, epigenetic drivers and pathology of neurodegenerative disease?
  • How does the heterogeneity of AD and other degenerative diseases dictate focusing on distinct subpopulations?

Alice Zhang, Verge Genomics
Richard Wade-Martins, University of Oxford
Tamara Maes, Oryzon Genomics S.A.

11.30 Single Domain Antibody Platform for Delivery of Biologics to the CNS

  • Combination of in vivo and in vitro phage selections allowed for identification of efficient, cross-species reactive, and safe CNS shuttles specific to TfR1 receptor
  • The shuttle mediates uptake of small peptides, antibodies and enzymes to the brain parenchyma, where these cargos can exert their physiologic/ therapeutic action

Krzysztof Wicher, Principal Scientist and Group Leader,
Ossianix

11.50 Strategies to Improve Penetration & Delivery to the Brain

  • Highlighting current data on innovative technological approaches such as chemical modifications and physical disruption for the delivery of therapeutics to the CNS
  • Exploring novel shuttle and trojan approaches for delivery of therapeutics across the brain-blood barrier

Robert Bell, Senior Principal Scientist & Lab Head of
Neurovascular Biology, Pfizer

12.10 Nose to Brain Delivery of Neuroprotective Amnion Derived ST266 Secretome

  • Intranasal delivery is an effective means to deposit large molecular weight proteins to the brain
  • Amnion derived secretome is neuroprotective and anti-inflammatory in optic nerve disease and traumatic injury models

Larry Brown, Executive Vice President R&D, Chief
Scientific Officer, Noveome Biotherapeutics

12.30 Session Q&A Panel

  • What passive and active mechanisms should be considered during the development and delivery of effective therapeutic interventions to central nervous system targets?
  • How can we best harness innovative methods including chemical modifications, Trojan horse approaches, physical targeting and disruption, nanoparticles,
    ultrasound, and other technologies?
  • What potential opportunities are there to catalyze development of novel treatments that cross the BBB from the preclinical to clinical phase with an emphasis on risks, levers, and potential collaborative efforts among sectors

Krzysztof Wicher, Ossianix
Robert Bell, Pfizer
Larry Brown, Noveome Biotherapeutics

13.00
Lunch & Networking

Addressing The Need for Integrative Disease Modelling

14.00
Progress and Challenges in the Development of Translational in Vivo Disease Modification Assays

Synopsis

  • Reviewing approaches to demonstrate disease modification in preclinical in vivo assays for neurodegenerative disorders
  • Exploring progress and hurdles towards translational assays: keeping the clinical goal in sight
  • Optimizing the application of currently available in vivo assays to exploit their strengths
  • Highlighting Huntington’s disease, ALS, and Parkinson’s disease research

14.20
Profiling Specific Cell Populations in Human Brain Tissue to Identify New Targets

Synopsis

  • Demonstrating new insights about healthy and disease states as well as aging through Cerevance’s molecular profiling of neuronal and glial cell nuclei
  • Highlighting how our large-scale approach provides an alternative to relying on animal models, iPS cells and single cell analysis
  • Through comparative analysis, we are identifying potentially new drug targets that are highly selectively expressed in cell populations and circuitry that are most vulnerable in neurodegenerative diseases

14.40
Session Q&A Panel

Synopsis

  • In vitro, in vivo and/or in silico analyses: where should be applying our resources to bridge the translational gap in neurodegenerative research?
  • How can the study of genotype-phenotype interactions be integrated to enhance the translation of modelling systems?
  • Are we able to cost-effectively scale up advanced blood-brain barrier models to make high throughput and or high content screening a reality?
  • Which of these dynamic models most effectively and accurately models the blood-brain barrier to prove selective drug delivery and distribution?
  • What advances have been made using human iPSc-derived neurons to model key mechanisms of pathology and their applications to stimulate drug discovery?

15.00
Afternoon Refreshments & Networking

Exploring the Utility of Non Human Primate Models in the Study of Neurodegeneration

16.00
Evaluating Translatability: Relevance of Rodent & Nonhuman Primate Preclinical Models of Cognitive Impairment to Clinical Drug Development

  • Jay Schneider Professor, Pathology, Anatomy and Cell Biology, Director, Parkinson’s Disease Research Unit, Thomas Jefferson University

Synopsis

  • Reiterating cognitive impairment as a key component of various CNS disorders as well as an important potential adverse effect of medications
  • Reviewing similarities and differences in homology between rodent/human and nonhuman primate/human in relationships between brain organization and cognitive capacity
  • Highlighting advantages and disadvantages of rodent and nonhuman primate models of cognitive dysfunction
  • Demonstrating translational successes/failures of rodent and nonhuman primate cognition models

16.20
Translational Value of Non-Human Primate Models of Motor Impairment and Disease Progression in Parkinson’s Disease

Synopsis

  • Demonstrating the value of MPTP-lesioned non-human primates in predicting Phase II efficacy of novel treatments for motor symptoms, and motor side-effects of treatment, in Parkinson’s disease
  • Reviewing the limitations of MPTP-lesioned non-human primate in predicting Phase II efficacy in providing disease modifying benefit in Parkinson’s disease
  • Exploring recent progress and applications of alpha-synuclein-based non-human primate models for evaluating novel approaches to disease modification in Parkinson’s disease

16.40
Session Q&A Panel

  • Jay Schneider Professor, Pathology, Anatomy and Cell Biology, Director, Parkinson’s Disease Research Unit, Thomas Jefferson University
  • Jonathan Brotchie Co-Founder and Chairman, Atuka Inc.

Synopsis

  • How are new technologies converging to enhance primate specific neurodegenerative research?
  • Despite advances, how should we seek to overcome the technical challenges in the creation and analysis of transgenic primate models?
  • For which applications should primate models act as a critical tool in the advancement of neurodegenerative research?
  • How do we build the business case for their use, given cost and ethical considerations amongst recent advances in the development of lower order and cellular based models?

17.30
Closing Remarks & Close of Conference Day One